Twist Bioscience Corp (TWST) stock plummeted 5.08% in intraday trading on Tuesday, despite reporting solid first quarter fiscal 2025 results. The biotech company's revenue grew 24% year-over-year to $88.7 million, exceeding guidance, and gross margin improved to 48.3%, driven by operational efficiencies and higher revenue leverage.
However, investors appeared concerned about the company's growth prospects and outlook. During the earnings call, management acknowledged uncertainty in the academic market and challenges faced by certain customers in the cleantech and biopharma sectors due to the current economic environment.
While Twist Bioscience raised its full-year revenue guidance to $372 million to $379 million, representing growth of approximately 20% at the midpoint, the increase was primarily driven by the synthetic biology (SynBio) and biopharma services segments. The company narrowed its guidance range for the core NGS (Next-Generation Sequencing) segment, reflecting potential headwinds in this critical business area.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.